Antibiotic use is associated with SJ syndrome and toxic epidermal necrosis, with sulfonamides being the most common culprits.

Published Date: 17 Feb 2023

Antibiotic use linked to SJ syndrome and toxic epidermal necrosis, sulfonamides are worst culprits in new study...

Read Full News

Latest News

Knowledge CheckPoint: Essential Evidence on New and Emerging TYK2 Inhibitors in PsO

Knowledge CheckPoint: Essential Evidence on New and Emerging TYK2 Inhibitors in PsO

Psoriasis Consult in Action: When Topical Treatments Aren't Doing the Trick

Psoriasis Consult in Action: When Topical Treatments Aren't Doing the Trick

AAD Expert Video Roundtable: Expert Video Roundtable from the American Academy of Dermatology

Updates in Hidradenitis Suppurativa: Underlying Pathogenic Mechanisms and Novel Targeted Treatments

Updates in Hidradenitis Suppurativa: Underlying Pathogenic Mechanisms and Novel Targeted Treatments

AAD Video Pearls: Video Pearls from the American Academy of Dermatology

AAD Future Focus: Future Focus from the American Academy of Dermatology

Todays Updates

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

GuCS: Genitourinary Cancers Symposium

GuCS Video Pearls: Video Pearls from the Genitourinary Cancers Symposium

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

Todays Updates

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

GuCS: Genitourinary Cancers Symposium

GuCS Video Pearls: Video Pearls from the Genitourinary Cancers Symposium

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

Latest News

Knowledge CheckPoint: Essential Evidence on New and Emerging TYK2 Inhibitors in PsO

Psoriasis Consult in Action: When Topical Treatments Aren't Doing the Trick

Updates in Hidradenitis Suppurativa: Underlying Pathogenic Mechanisms and Novel Targeted Treatments

News All Time

GLP-1 Drugs May Benefit Cancer Patients With Brain Lesions

Retrospective study finds link between blockbuster drugs and longer survival

Make the Diagnosis: From a Bone Marrow Transplant to a Huge Rash. What’s Your Diagnosis?

A 49-year-old man with a history of acute myeloid leukemia who received an allogeneic bone marrow transplant 2 weeks prior developed a widespread rash. Can you diagnose the patient?

FDA OKs First Drug for Liver Disease-Related Pruritus

Linerixibat approved for cholestatic itch in primary biliary cholangitis

FDA Withdraws Proposal for Tanning Bed Age Limit

Agency cites concerns raised in public comments; dermatologists emphasize risks for young people

'Potential Game Changer' for Psoriasis Gets Green Light From FDA

Oral IL-23 inhibitor icotrokinra achieved near-complete skin clearance in two-thirds of patients

GLP-1 Drugs Pick Up Another Win, This Time in Psoriatic Arthritis

Adding tirzepatide to ixekizumab significantly improved primary and key secondary outcomes

Resistant Dermatomyositis Improves Quickly, Significantly With Combination Drug

Brepocitinib significantly boosts global, all secondary dermatomyositis scores in VALOR trial

EULAR Updates Its Guidance on Managing Behcet's Syndrome

Takes recent clinical trials, drug introductions into account

'Incredible' Response Rates in Atopic Dermatitis With Drugs From China

Historically good results with IL-4 inhibitors raise questions with U.S. audience

New TYK2 Inhibitors for Psoriasis Achieve High Clearance Rates in Randomized Trials

Three-fourths of patients have 70-75% improvement at 16 weeks with zasocitinib, envudeucitinib

FDA Warns of Fatal Liver Injuries Tied to Drug It Wants Pulled From Market

Eight deaths and dozens of DILI cases linked to avacopan for ANCA-associated vasculitis

Is 'Butt Microneedling' the Secret to a Youthful Rear? Dermatologist Weighs In

Kelly Ripa recently discussed her attempt to stop her tush from aging

Despite Concerns Over Breast Screening, FDA OKs New Use for Dermal Filler

A postmarketing study will assess whether Radiesse interferes with breast imaging

Novel Therapies for Hidradenitis Suppurativa Produce Rapid, Deepening Responses

Responses include total clearance in up to 30% of patients treated with sonelokimab, povorcitinib

Quiz Time: What Drug Was Tied to 8 Deaths?

You passed medical training, now see if you can pass our weekly quiz

The Truth About Red Light Therapy Masks, According to a Dermatologist

Are these skin care devices all hype, or are there science-backed benefits?

Recommended News For You

HER3 Antibody Drug Conjugate Shows Promise in NSCLC

Researchers investigate risk of developing multiple primary cancers after surviving bowel cancer

AI tool identifies women at high risk of interval breast cancer

Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.

In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".

A new way to measure suicide risk?

Recommended Articles For You

Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond 

A Mural of Thrombus: Unlocking the Power of Art to Combat Cardiovascular Disease 

Navigating the Stages of Thyroid Cancer: A Guide for Patients 

The Future is Now: Navigating the Precision Revolution in Oncology Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Risk of a second cancer after early breast cancer is low, say new findings

2.

Atezolizumab Consolidation Impresses in High-Risk DLBCL

3.

WHO launches plan for free child cancer medicines

4.

Lentiviral Gene Therapy Shows Promise in Severe Hemophilia A

5.

Additional imaging techniques can detect early stage cancers missed by mammograms in women with dense breasts

1.

Expanding Oncology Frontiers: Rare Cancers, Breakthroughs, and Precision Medicine Advances

2.

Exploring New Solutions for MCV Low: Unlocking the Potential for Improved Health

3.

Navigating the Evolving Landscape of Oncology Clinical Trials in the Era of Precision Medicine

4.

Exploring the Potential of Bendamustine in Cancer Treatment

5.

The Dark Side of Melanoma: Uncovering the Risk Factors and Prevention Strategies

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective

2.

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

3.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI

4.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I

5.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot